Asha Nayak, MD, PHD

Medicare standing: 1 flag on the record; Listed below.
Plans that list them: Not verified; Not the same as out of network.
Office: 1

On the public record

Medicare does not list them as allowed to order and refer

Offices

1 location

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Nayak’s office at (650) 493-5000 to ask if they take your plan before you enroll.

California Medical Board record

Licence A69881 · Current

Licensed to practise in California · since 1999 · expires 2027-05-31 · University of Colorado School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Money from drug and device companies

$95 in 2025

Sort by

Industry payments by year

2025	1	1	None	$95
2020	1	5	$34,583	$38,302
2019	2	3	None	$142

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Janssen Research & Development	None	$95	1 payment Meals · 2025-01-12 · $95

See the published payment

Sort by

Every published payment

Janssen Research & Development	Meals · 2025-01-12	None	$95

See earlier years (2020, 2019)

2020: $38,302

Sort by

Payments by company in 2020

Sage Therapeutics	None	$38,302	5 payments Paid to speak or teach · 2020-08-06 · $9,583 Paid to speak or teach · 2020-06-11 · $12,500 Travel · 2020-01-22 · $3,627 Meals · 2020-01-22 · $92 Paid to speak or teach · 2020-01-06 · $12,500

2019: $142

Sort by

Payments by company in 2019

Shire North American Group	Gammagard Liquid	$86	1 payment Meals for Gammagard Liquid · 2019-02-21 · $86
Sage Therapeutics	None	$56	2 payments Meals · 2019-12-18 · $37 Meals · 2019-12-18 · $20

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

AstraZeneca UK Limited · An Observational Multi-Center Study To Evaluate Real-World Treatment Outcomes of Durvalumab-Based Regimens in Hepatobiliary Cancers · 2025	Their institution	$10,727

Professional record

NPI: 1306921168
Licence: CA A69881California A69881: Current · expires 2027-05-31

More record details

Sole proprietor: No
Taxonomy: Internal medicine (207R00000X)
Mailing address: 2275 Sharon Rd Apt 110, Menlo Park, CA, 94025
NPI first listed: 2006-10-27
NPI last updated: 2007-07-08

This is when the NPI record was last certified, not a medical board exam.